Cargando…

CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer

In this study, we aimed to develop a population pharmacokinetic model for CPT‐11 and to use the Bayesian method to estimate CPT‐11 pharmacokinetic parameters in each of 43 patients who received combined therapy consisting of CPT‐11 and etoposide. The group was divided into first and second data sets...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Nobuyuki, Tamura, Tomohide, Karato, Atsuya, Uenaka, Kazunori, Eguchi, Kenji, Shinkai, Tetsu, Ohe, Yuichiro, Oshita, Fumihiro, Arioka, Hitoshi, Nakashima, Hajime, Shiraishi, Jun‐ichi, Fukuda, Minoru, Higuchi, Shun, Saijo, Nagahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1994
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919593/ https://www.ncbi.nlm.nih.gov/pubmed/7961128 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02977.x

Ejemplares similares

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions
por: Oshita, Fumihiro, et al.
Publicado: (1995)

A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin
por: Ohmatsu, Hironobu, et al.
Publicado: (1994)

Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging
por: Miya, Toshimichi, et al.
Publicado: (1992)

Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer
por: Eguchi, Kenji, et al.
Publicado: (1990)

Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay
por: Oshita, Fumihiro, et al.
Publicado: (1995)

Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D)
por: Sasaki, Yasutsuna, et al.
Publicado: (1990)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene‐specific Damage between Cisplatin‐ or VP‐16‐resistant and Sensitive Lung Cancer Cell Lines
por: Oshita, Fumihiro, et al.
Publicado: (1994)

Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity
por: Shinkai, Tetsu, et al.
Publicado: (1989)

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level
por: Sano, Tetsuro, et al.
Publicado: (1988)

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs
por: Ohtsu, Atsushi, et al.
Publicado: (1989)

Basic Design Considerations for Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1992)

Guidelines for Analysis and Reporting of Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1993)

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
por: Bissett, D, et al.
Publicado: (2004)

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors
por: Murakami, Haruyasu, et al.
Publicado: (2010)

CORRECTION
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors
por: Ueda, Yutaka, et al.
Publicado: (2010)

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
por: Fukumoto, Hisao, et al.
Publicado: (1997)

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
por: Schoemaker, N E, et al.
Publicado: (2002)

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1997)

Progress in treatment of small-cell lung cancer: role of CPT-11
por: Saijo, N
Publicado: (2003)

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11
por: Ogasawara, Hayato, et al.
Publicado: (1995)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis
por: Fukuda, Minoru, et al.
Publicado: (1996)

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519
por: Nakamura, Takashi, et al.
Publicado: (2001)

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
por: Yamada, Kazuhiko, et al.
Publicado: (2010)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
por: Matsumoto, Kazuaki, et al.
Publicado: (2016)

Analysis of Pharmacokinetics in the Cochlea of the Inner Ear
por: Sawamura, Seishiro, et al.
Publicado: (2021)

Pharmacokinetics /
por: Gibaldi, Milo
Publicado: (1982)

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene
por: Kurokawa, Hirokazu, et al.
Publicado: (1997)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
por: Okusaka, Takuji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qkivpnqimv2r17jefih6opp2u0